| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
4-Propionamidophenol does not have a single defined pharmacological target but is a chemical intermediate. It is an important intermediate of alkanolamine derivatives with beta-adrenergic blocking activity. Beta-adrenergic blocking agents target β-adrenergic receptors, which are involved in the regulation of heart rate and blood pressure.
|
|---|---|
| ln Vitro |
4-Propionamidophenol is primarily used as a chemical intermediate rather than for its pharmacological activity. It is an analog of p-acetamidophenol. It can be used in the study of diseases such as heart disease and hypertension, likely as a precursor or reference compound.
|
| ln Vivo |
In vivo, 4-Propionamidophenol is not used as a therapeutic agent but as a research chemical. Its potential in vivo effects are related to its role as an intermediate for compounds with beta-adrenergic blocking activity, which could affect heart rate and blood pressure. However, the compound itself is not a drug and is used for research and synthesis purposes.
|
| Enzyme Assay |
In vitro assays for 4-Propionamidophenol typically involve its use as a reference standard or chemical intermediate. It can be used in analytical method development for the quantification of related compounds. Its physicochemical properties, such as solubility and stability, can be characterized using standard analytical techniques.
|
| Cell Assay |
For in vitro cell-based assays, 4-Propionamidophenol can be used to study the effects of its derivatives or as a control compound in studies of beta-adrenergic signaling. However, its primary use is as a chemical intermediate. Cell viability and other cellular effects can be assessed using standard assays if needed.
|
| Animal Protocol |
In vivo animal studies with 4-Propionamidophenol are limited, as the compound is primarily used as a chemical intermediate. It could be used in studies to evaluate the pharmacology of its derivatives with beta-adrenergic blocking activity. However, specific published protocols are limited. The compound is not intended for therapeutic use.
|
| ADME/Pharmacokinetics |
4-Propionamidophenol (CAS: 1693-37-4) has a molecular weight of 165.19 g/mol and a molecular formula of C₉H₁₁NO₂. Appearance: Off-white to gray solid powder. Melting Point: 170-172ºC. LogP: 0.87. Storage: Powder -20°C 3 years, 4°C 2 years. Solubility: DMSO ~250 mg/mL.
|
| Toxicity/Toxicokinetics |
4-Propionamidophenol is a research compound and is not approved for human therapeutic use. It is considered to have a low toxicity profile as a chemical intermediate. Standard laboratory safety precautions should be followed when handling the compound. It is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
4-Propionamidophenol is a p-acetamidophenol analog and an important intermediate of alkanolamine derivatives with beta-adrenergic blocking activity. It can be used in the study of diseases such as heart disease and hypertension. It is not an FDA-approved drug and is intended for research use only.
|
| Molecular Formula |
C9H11NO2
|
|---|---|
| Molecular Weight |
165.18914
|
| Exact Mass |
165.078
|
| CAS # |
1693-37-4
|
| PubChem CID |
74325
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
389.9±25.0 °C at 760 mmHg
|
| Melting Point |
170-172ºC
|
| Flash Point |
189.6±23.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.600
|
| LogP |
0.87
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
151
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC(=O)NC1=CC=C(C=C1)O
|
| InChi Key |
SSMYTAQHMUHRSK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H11NO2/c1-2-9(12)10-7-3-5-8(11)6-4-7/h3-6,11H,2H2,1H3,(H,10,12)
|
| Chemical Name |
N-(4-hydroxyphenyl)propanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1513.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (12.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0536 mL | 30.2682 mL | 60.5364 mL | |
| 5 mM | 1.2107 mL | 6.0536 mL | 12.1073 mL | |
| 10 mM | 0.6054 mL | 3.0268 mL | 6.0536 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
